Revance Therapeutics (NASDAQ:RVNC) received a $50.00 price target from equities researchers at Cantor Fitzgerald in a research note issued on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 43.27% from the company’s current price.
A number of other equities analysts have also issued reports on RVNC. Zacks Investment Research lowered Revance Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 7th. Piper Jaffray Companies reissued a “buy” rating and set a $28.00 price target on shares of Revance Therapeutics in a report on Friday, October 27th. Mizuho started coverage on Revance Therapeutics in a report on Thursday, November 16th. They set a “buy” rating and a $37.00 price target on the stock. Barclays started coverage on Revance Therapeutics in a report on Monday, November 27th. They set an “overweight” rating and a $31.00 price target on the stock. Finally, ValuEngine lowered Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Revance Therapeutics presently has a consensus rating of “Buy” and an average price target of $43.33.
Shares of Revance Therapeutics (NASDAQ:RVNC) opened at $34.90 on Thursday. Revance Therapeutics has a 52-week low of $18.00 and a 52-week high of $37.45. The company has a market capitalization of $1,080.00, a PE ratio of -9.16 and a beta of 1.62.
In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of Revance Therapeutics stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total value of $189,544.00. Following the sale, the chief executive officer now owns 133,188 shares of the company’s stock, valued at approximately $3,321,708.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark J. Foley acquired 20,000 shares of the stock in a transaction on Tuesday, November 7th. The stock was acquired at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at approximately $161,760. The disclosure for this purchase can be found here. Insiders sold a total of 36,426 shares of company stock worth $956,026 in the last ninety days. 18.86% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its holdings in Revance Therapeutics by 4.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock valued at $95,743,000 after purchasing an additional 166,759 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Revance Therapeutics by 13.1% in the 2nd quarter. Franklin Resources Inc. now owns 3,375,238 shares of the biopharmaceutical company’s stock valued at $89,106,000 after purchasing an additional 391,638 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Revance Therapeutics by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock valued at $24,595,000 after purchasing an additional 63,505 shares in the last quarter. State Street Corp boosted its holdings in Revance Therapeutics by 0.6% in the 2nd quarter. State Street Corp now owns 452,490 shares of the biopharmaceutical company’s stock valued at $11,944,000 after purchasing an additional 2,637 shares in the last quarter. Finally, PointState Capital LP boosted its holdings in Revance Therapeutics by 58.5% in the 2nd quarter. PointState Capital LP now owns 438,200 shares of the biopharmaceutical company’s stock valued at $11,568,000 after purchasing an additional 161,700 shares in the last quarter. 76.69% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3128069/revance-therapeutics-rvnc-pt-set-at-50-00-by-cantor-fitzgerald.html.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.